A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells

The use of recombinant interleukin-2 (IL-2) as a therapeutic protein has been limited by significant toxicities despite its demonstrated ability to induce durable tumor-regression in cancer patients. The adverse events and limited efficacy of IL-2 treatment are due to the preferential binding of IL-...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Katherine E., Lorentsen, Kyle J., Malik-Chaudhry, Harbani K., Loughlin, Kaitlyn, Basappa, Harish Medlari, Hartstein, Sharon, Ahmil, Ghenima, Allen, Nicole S., Avanzino, Brian C., Balasubramani, Aarti, Boudreau, Andrew A., Chang, Karen, Cuturi, Maria-Cristina, Davison, Laura M., Ho, Dennis M., Iyer, Suhasini, Rangaswamy, Udaya S., Sankaran, Preethi, Schellenberger, Ute, Buelow, Roland, Trinklein, Nathan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134639/
https://www.ncbi.nlm.nih.gov/pubmed/34011961
http://dx.doi.org/10.1038/s41598-021-90096-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134639/
https://www.ncbi.nlm.nih.gov/pubmed/34011961
http://dx.doi.org/10.1038/s41598-021-90096-8

Ejemplares similares